Pegylated Recombinant Human Arginase I
Hepatocellular Carcinoma
Bio-Cancer Treatment International LimitedPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 65/ 100
Competitive context
521 Active assets in the Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Huaier Granule Tongji Hospital | Phase 4 | BBB |
Adefovir Bukwang Pharmaceutical | Phase 4 | BBB |
Sorafenib Bayer | Phase 4 | BBB |
Carboplatin AstraZeneca | Phase 4 | BB |
Theprubicin RWTH Aachen University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Pegylated Recombinant Human Arginase I is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →